Co-Diagnostics Inc.

Co-Diagnostics Inc. is a molecular diagnostics company that develops, manufactures, and sells reagents for diagnostic tests relying on the detection and analysis of nucleic acid molecules. It operates in the United States and internationally, focusing on polymerase chain reaction (PCR) technologies for point-of-care and at-home testing. The company's Co-Dx PCR platform enables rapid molecular testing, supporting diagnostics for infectious diseases including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. Co-Diagnostics Inc. also advances tools for liquid biopsy in cancer screening and agricultural applications, automating complex procedures to deliver low-cost, efficient solutions. Through its joint venture CoSara Diagnostics Pvt. Ltd. in India, it pursues decentralized PCR testing, including proprietary sample preparation instruments for primary health centers. Founded in 2013 and headquartered in Salt Lake City, Utah, Co-Diagnostics Inc. plays a key role in accessible molecular diagnostics across healthcare, oncology, and agriculture sectors.

Sector

Healthcare

Industry

Medical Devices

CEO

Mr. Dwight H. Egan

Employees

115

Headquarters

Salt Lake City, UT, United States

Website

co-dx.com